Skip to content
Search

Latest Stories

Recall report of blood pressure drugs 'misleading'

The Royal Pharmaceutical Society (RPS) has confirmed that the recall of blood pressure drugs amlodipine and olmesartan by the Food and Drug Administration is only for the US market and will not have any impact in the UK.

MHRA also clarified that the manufacturer of these drugs, Macleod Pharmaceuticals, does not supply amlodipine medicines in the UK.

It was published online in both the Daily Record and Daily Express on the morning of Monday, March 21, that the drugs had been recalled in the US by the FDA due to deviations from standard manufacturing protocols by the manufacturer.


RPS intervened to ensure the articles were edited to make clear that this is not an issue in the UK after confirmation from the MHRA. Amlodipine tablets from Macleod Pharmaceuticals aren't available for wholesale distribution in the UK.

An MHRA statement said: “The MHRA has confirmed that the recall of combined Amlodipine/Olmesartan Medoxomil tablets 10 mg/20 mg, batch number BAD62101A (expiry Feb 24), is for the US market only – while Macleods Pharma does supply other medicines to the UK, this particular product is not available here.”

"Patients seeking advice can be reassured that the amlodipine and olmesartan provided by the NHS is not affected by the recall in the USA," assures RPS.

More For You

Sukhi Basra named NPA vice-chair in historic leadership update with Olivier Picard as new chair

Olivier Picard steps up as NPA chair, Basra as vice-chair

Olivier Picard named new NPA chair

The National Pharmacy Association (NPA) has announced Olivier Picard as the organisation’s new chair.

Picard replaces Nick Kaye whose term comes to an end this week.

Keep ReadingShow less
 RPS honours Professor Tony Avery OBE for excellence in prescribing safety and patient care

Professor Tony Avery OBE

Pic credit: RPS

Professor Tony Avery OBE awarded RPS Honorary Fellowship

The Royal Pharmaceutical Society (RPS) Assembly has awarded an Honorary Fellowship to Professor Tony Avery OBE in recognition of his outstanding contribution to prescribing safety and patient care.

The Honorary Fellowship is given to those who are not eligible for membership of the Society but have either attained a distinction in a particular aspect or aspects of pharmacy, made a distinctive contribution to pharmacy or the RPS, distinguished themselves in any branches of knowledge referred to in the objects of the Society or achieved eminence in public life.

Keep ReadingShow less
US-UK pharmaceutical trade concerns as Liberal Democrat MPs urge protection from Trump tariffs.

UK prime minster Sir Keir Starmer with US president Donald Trump

Pic credit: Getty images

Pharma sector needs protecting from Trump tariffs, warn MPs

A group of Liberal Democrat MPs have written to health secretary Wes Streeting urging him to protect the pharmaceutical industry from US president Donald Trump’s trade war.

The five ministers from Oxfordshire, Olly Glover, Layla Moran, Calum Miller, Charlie Maynard, and Freddie van Mierlo, have warned that Trump’s campaign to raise tariffs has already led to “catastrophic damage”.

Keep ReadingShow less
Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less